CytomX Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview

CytomX Therapeutics

04/11/2023 03:06

* CytomX Therapeutics Inc  CTMX.OQ   CTMX.O  is expected
to show a
fall in quarterly revenue when it reports  results 
    * The South San Francisco California-based  company is
expected to
report  a 16.4% decrease in revenue to $14.141 million from
$16.92 million a year ago, according to the mean estimate from 9
analysts, based on LSEG data. 
    * ​Refinitiv's mean analyst estimate for CytomX Therapeutics
Inc
is for a loss of 19 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 7
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for CytomX
Therapeutics Inc is $2.13​, above​ its last closing price
of $1.26. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.18       -0.20      -0.02     Beat    90.2
 Mar. 31 2023  -0.12       -0.11      -0.05     Beat    52.7
 Dec. 31 2022  -0.17       -0.24      -0.43     Missed  -82.5​
 Sep. 30 2022  -0.29       -0.31      -0.35     Missed  -14.5
 ​​Jun.        -0.36       -0.36      -0.37     Missed  -2.8
 30 2022                                                
 Mar. 31 2022  -0.38       -0.36      -0.37     Missed  -1.8​
 Dec. 31 2021  -0.14       -0.28      -0.40     Missed  -41.7
 Sep. 30 2021  -0.31       -0.31      -0.35     Missed  -12
 This summary was machine generated November 4 at 03:06 GMT.  All
figures in US dollars  unless otherwise stated